Comparing Initial and Expanded Access INDs: Purpose, Process, and Key Regulatory Differences

Introduction: What Is an IND and Why Are There Different Types?

An Investigational New Drug (IND) application allows sponsors to legally administer an unapproved drug to humans. While most INDs are submitted to initiate clinical trials (initial INDs), the U.S. Food and Drug Administration (FDA) also provides a mechanism called Expanded Access IND — commonly referred to as “compassionate use” — for patients with serious or life-threatening conditions who lack other treatment options.

Understanding the differences between initial and expanded access INDs is critical for clinical researchers, regulatory professionals, and healthcare providers seeking investigational treatment outside of a formal trial setting.

Sponsors frequently consult global databases like ANZCTR to track investigational use programs and eligibility standards in other regions.

What Is an Initial IND?

The Initial IND, often called a “commercial IND,” is submitted by sponsors to begin clinical trials of an investigational drug. The purpose is to generate safety and efficacy data that can support a future marketing application.

An initial IND must include:

• Nonclinical pharmacology and toxicology data
• Chemistry, Manufacturing, and Controls (CMC) information
• A complete clinical trial protocol
• Investigator brochures and regulatory forms

The FDA reviews initial INDs within 30 days to determine if the proposed trial may proceed or if a clinical hold is necessary.

What Is an Expanded Access IND?

The Expanded Access IND (EA-IND) permits the use of an investigational drug outside of a clinical trial, usually for a single patient, intermediate-size population, or treatment group. These programs are designed for patients with serious or life-threatening conditions who cannot enroll in a trial and have no satisfactory alternatives.

EA-INDs are generally non-commercial and focus on individual patient treatment rather than drug development.

Three Categories of Expanded Access

• Single-Patient IND: For an individual patient, often under emergency use
• Intermediate-Size IND: For a group of patients with the same condition
• Treatment IND: For widespread access during late-stage development

Regulatory Requirements: Initial vs Expanded Access IND

While both types of INDs require safety oversight, there are important differences in submission content and review timelines.

Sample Table: Comparison of Initial and Expanded Access INDs

Submission Pathways, Documentation, and Compliance Tips

Submission Process for Initial INDs

Initial INDs must follow the full CTD structure with modules for administrative forms, summaries, quality, nonclinical and clinical data. Key documents include:

• FDA Form 1571 (application form)
• Form 1572 (investigator statement)
• Clinical protocol and investigator brochure
• CMC and toxicology reports

Sponsors must submit in electronic Common Technical Document (eCTD) format via the FDA’s Electronic Submissions Gateway (ESG).

Submission Process for Expanded Access INDs

EA-INDs, especially for single-patient use, have simplified submission requirements. In emergency situations, the sponsor may obtain verbal authorization from the FDA followed by a written submission within 15 days.

Required documents typically include:

• FDA Form 3926 (streamlined form for individual patients)
• Informed consent documentation
• Letter of authorization from the drug manufacturer
• Clinical rationale and treatment plan

IRB approval is also required unless exempted due to urgency.

Ethical and Safety Oversight

Regardless of IND type, the FDA requires that the investigational product is administered under adequate safety monitoring and ethical oversight. Sponsors must:

• Report serious adverse events (SAEs) within mandated timelines
• Submit annual reports for ongoing INDs
• Ensure data integrity and patient protection

For EA-INDs, adverse events must be reported under 21 CFR 312.32, and follow-up reports may be requested if the use extends beyond a single dose.

When to Use Which Pathway?

The decision between an initial IND and an expanded access IND depends on the goal:

• Use an initial IND when conducting a formal study to support drug development or marketing authorization
• Use an expanded access IND when treating an individual patient with no clinical trial options

Both require FDA approval, but the intent and regulatory burden differ significantly.

Case Example: Expanded Access for a Rare Pediatric Disease

A pediatric neurologist submitted a single-patient EA-IND for a child with a rare genetic disorder unresponsive to approved therapies. The investigational product had shown early promise in Phase 1 trials, but the patient was not eligible due to age restrictions.

The sponsor submitted Form 3926, IRB approval, manufacturer’s authorization, and treatment plan. FDA approval was granted within 48 hours under emergency use provisions. Treatment commenced, and safety data were later integrated into the sponsor’s development program.

Conclusion: Making the Right IND Choice

Initial and Expanded Access INDs serve very different but equally important roles in the U.S. drug development and access ecosystem. While initial INDs drive innovation through structured clinical trials, expanded access INDs ensure that patients facing life-threatening conditions can obtain investigational treatments when no other options exist.

Regulatory teams must understand the procedural, ethical, and strategic considerations of both types. With proper planning, documentation, and adherence to FDA guidelines, both pathways can be used effectively to advance clinical research and patient care.